Last reviewed · How we verify

Elucirem (Gadopiclenol) — Competitive Intelligence Brief

Elucirem (Gadopiclenol) (Elucirem (Gadopiclenol)) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Gadolinium-based MRI contrast agent. Area: Diagnostic Imaging.

marketed Gadolinium-based MRI contrast agent Water protons (T1 relaxation enhancement) Diagnostic Imaging Small molecule Live · refreshed every 30 min

Target snapshot

Elucirem (Gadopiclenol) (Elucirem (Gadopiclenol)) — Johns Hopkins University. Gadopiclenol is a gadolinium-based contrast agent that enhances magnetic resonance imaging (MRI) by shortening T1 relaxation time of water protons in tissues.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Elucirem (Gadopiclenol) TARGET Elucirem (Gadopiclenol) Johns Hopkins University marketed Gadolinium-based MRI contrast agent Water protons (T1 relaxation enhancement)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Gadolinium-based MRI contrast agent class)

  1. Johns Hopkins University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Elucirem (Gadopiclenol) — Competitive Intelligence Brief. https://druglandscape.com/ci/elucirem-gadopiclenol. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: